Plant Alkaloid Narciclasine Shows Promise Against Aggressive Childhood Cancer in Lab Study

Neuroblastoma remains one of the most formidable challenges in pediatric oncology. Arising from neural crest-derived cells of the sympathetic nervous system, this malignancy accounts for a striking proportion of cancer deaths in early childhood, and its most aggressive forms continue to defy even the most intensive multimodal treatment regimens. Now, a team of researchers at Bursa Uludag University in Türkiye has reported that narciclasine, a naturally occurring alkaloid extracted from plants of the Amaryllidaceae family such as the red spider lily, Lycoris radiata, can suppress the growth and spread of neuroblastoma cells in the laboratory. Writing in the journal Medical Oncology, the group describes how nanomolar concentrations of the compound reduced proliferation, migration, and colony formation in SH-SY5Y neuroblastoma cells while simultaneously triggering apoptotic cell death and DNA damage, all through a signaling axis that cancer biologists have long coveted as a therapeutic target.

The appeal of narciclasine lies in its pedigree. Alkaloids from the Amaryllidaceae family have attracted attention for decades because of their diverse pharmacological activities, ranging from anti-inflammatory effects to potent cytotoxicity against tumor cells. Previous work by other groups has shown that narciclasine can kill cancer cells by activating both the death receptor and mitochondrial apoptotic pathways, that it targets the translation elongation factor eEF1A in melanoma cells, and that it acts as a GTP-ase targeting agent against brain cancers. More recently, studies in esophageal, gastric, colon, oral, and breast cancers have implicated a variety of molecular mechanisms, from FAK inhibition to STAT3 suppression and topoisomerase I blockade. What remained poorly understood, however, was whether any of this activity extended to neuroblastoma, a tumor whose biology differs markedly from the adult carcinomas where most of this earlier work was performed.

To fill that gap, the research team, led by Ceren Oy and Sema Serter Kocoglu of the Department of Histology and Embryology, subjected SH-SY5Y cells, a widely used human neuroblastoma line, to a battery of assays designed to interrogate every hallmark of malignant behavior. Cell viability was quantified with the CCK-8 colorimetric assay, a sensitive readout of metabolic activity that has become a standard first screen for candidate drugs. The investigators tested a range of narciclasine concentrations and found that 50 and 100 nanomolar doses significantly reduced the viability of the neuroblastoma cells. Critically, when the same doses were applied to human umbilical vein endothelial cells, or HUVECs, a common non-malignant comparator, the cytotoxic effect was comparatively lower, an early hint that the compound might discriminate between tumor and healthy tissue, at least under the conditions tested.

With those two concentrations selected as the working doses, the team moved on to the central question of proliferation. Using immunofluorescence staining for Ki67, a nuclear protein expressed exclusively in actively dividing cells, they observed a marked decrease in the fraction of Ki67-positive neuroblastoma cells after narciclasine treatment. Proliferation is the engine of tumor expansion, and its suppression at such low drug concentrations is notable. The finding echoes earlier reports in esophageal cancer cells, where narciclasine was shown to curb proliferation through inhibition of the focal adhesion kinase, or FAK, signaling pathway, and it aligns with the broader literature on Amaryllidaceae alkaloids as cell cycle modulators.

Migration and metastatic potential were assessed next, using the wound-healing assay, in which a scratch is made across a confluent cell monolayer and the rate at which cells close the gap is measured as a proxy for motility. Narciclasine-treated cells closed the wound more slowly than untreated controls, indicating impaired migratory capacity. Colony formation assays reinforced the picture: the ability of individual cells to anchor independently and proliferate into visible colonies, a laboratory correlate of tumorigenic potential, was substantially reduced. For a cancer like neuroblastoma, whose clinical course is so often defined by metastatic spread, any agent that blunts motility in vitro is of considerable interest, particularly one that appears to act on the cytoskeletal and adhesion machinery through FAK.

The apoptotic results were equally striking. TUNEL staining, which detects the fragmented DNA characteristic of programmed cell death, revealed a significant increase in apoptotic cells following narciclasine exposure, and immunofluorescence for cleaved caspase-3, the executioner enzyme of apoptosis, showed correspondingly enhanced immunoreactivity. In parallel, the COMET assay, a single-cell gel electrophoresis technique that visualizes DNA strand breaks as a comet-like tail of migrated genetic material, demonstrated increased DNA damage in the treated cells. Together, these findings suggest that narciclasine pushes neuroblastoma cells toward a self-destructive fate while inflicting genotoxic stress that may itself contribute to the apoptotic signal.

The mechanistic core of the study lies in the FAK/PI3K pathway. Focal adhesion kinase is a cytoplasmic tyrosine kinase that integrates signals from cell adhesion receptors and growth factor pathways, and it is frequently overactive in aggressive tumors, including neuroblastoma, where prior work has shown that inhibiting FAK decreases tumor growth. Downstream of FAK, phosphoinositide 3-kinase, or PI3K, drives survival and growth signaling through the Akt axis, making the combined FAK/PI3K module a linchpin of malignant behavior. Using both immunohistochemistry and Western blot analysis, the Turkish team demonstrated that narciclasine treatment reduced the expression levels of both FAK and PI3K in the neuroblastoma cells, providing a coherent molecular explanation for the observed collapse in proliferation and migration.

This mechanism places the new findings within a rapidly growing body of literature on narciclasine’s anticancer pharmacology. In esophageal cancer, the compound suppresses proliferation and migration by inhibiting FAK signaling; in gastric cancer, it induces autophagy-mediated apoptosis through the Akt/mTOR pathway; in colon carcinoma, it triggers apoptosis by blocking the IL-17A/Act1/TRAF6/NF-κB cascade; and in tamoxifen-resistant breast cancer, it targets STAT3 through distinct mechanisms. A 2025 study further proposed narciclasine as a means of overcoming EGFR-TKI resistance in non-small cell lung cancer. The convergence of these reports on adhesion, survival, and inflammatory signaling pathways suggests that the alkaloid may act on a limited set of master regulators whose suppression is lethal to many tumor types, and the present study extends that logic to a pediatric solid tumor for the first time.

The clinical context makes the work timely. Neuroblastoma treatment has seen incremental advances, including anti-GD2 monoclonal antibody therapy and targeted agents, but toxicity remains a persistent concern, as illustrated by recent reports of pulmonary toxicity associated with combination regimens. Molecular targeting therapies for neuroblastoma have progressed, yet significant challenges persist, and the search for agents that are both effective and better tolerated continues. The observation that narciclasine exerted comparatively lower cytotoxicity against non-malignant HUVEC cells at the effective neuroblastoma doses is an early but encouraging sign of a therapeutic window, though the authors and outside observers alike would caution that in vitro selectivity is a far cry from clinical safety.

Indeed, the researchers themselves are careful to frame the study as a starting point rather than a conclusion. Their findings, they write, suggest that narciclasine exerts anti-neuroblastoma effects associated with reduced proliferative and migratory activity, increased apoptotic response, and modulation of FAK/PI3K-associated signaling in SH-SY5Y cells, but further studies are needed to clarify the precise molecular basis and therapeutic relevance of these effects. Key questions remain: whether the results hold in additional neuroblastoma cell lines, particularly MYCN-amplified high-risk variants; whether the compound is active in animal models of metastatic disease; how narciclasine’s known effects on translation elongation and other pathways interact with the FAK/PI3K axis; and whether pharmacokinetic and toxicity profiles can support eventual clinical testing in children. The work, supported by the Bursa Uludag University Scientific Research Projects Unit, was published on 29 August 2026 as an original paper in Medical Oncology, volume 43, article 261. For now, it stands as a compelling proof of concept that a molecule first isolated from the bulbs of an ornamental lily may one day inform new strategies against one of childhood’s most stubborn cancers.

Subject of Research: Effects of the plant alkaloid narciclasine on neuroblastoma cell proliferation, migration, apoptosis, and FAK/PI3K signaling

Article Title: Narciclasine reduces proliferation and migration of neuroblastoma cells and decreases FAK/PI3K pathway activation

Article References: Oy, C., Serter Kocoglu, S., Isıklar, S., & Gok Yurtseven, D. (2026). Narciclasine reduces proliferation and migration of neuroblastoma cells and decreases FAK/PI3K pathway activation. Medical Oncology, 43(10), Article 261. https://doi.org/10.1007/s12032-026-03359-7

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03359-7

Keywords: narciclasine, neuroblastoma, FAK/PI3K pathway, apoptosis, DNA damage, SH-SY5Y cells, Amaryllidaceae alkaloids, pediatric oncology, cell migration, Ki67, natural products, signal transduction